Suppressor tRNA-mediated conditionally replicating live vaccine effectively protects pigs against Seneca Valley virus challenge.

IF 7.2 1区 医学 Q1 IMMUNOLOGY
Xinghua Chen, Xiangmin Li, Nan Cao, Meiting Li, Linxing Tian, Pan Hu, Jian Du, Lingai Meng, Chao Zhang, Chunwei Li, Zihui Hu, Jinyan Zhang, Ping Qian
{"title":"Suppressor tRNA-mediated conditionally replicating live vaccine effectively protects pigs against Seneca Valley virus challenge.","authors":"Xinghua Chen, Xiangmin Li, Nan Cao, Meiting Li, Linxing Tian, Pan Hu, Jian Du, Lingai Meng, Chao Zhang, Chunwei Li, Zihui Hu, Jinyan Zhang, Ping Qian","doi":"10.1038/s41541-026-01507-8","DOIUrl":null,"url":null,"abstract":"<p><p>Seneca Valley virus (SVV) causes porcine idiopathic vesicular disease, severely endangering the economic benefits of the swine industry. Artificial control of viral replication via the introduction of premature termination codons (PTCs) into the viral genome using suppressor tRNAs (sup-tRNAs) is a promising strategy for developing efficient vaccines. In this study, optimization of the SVV 3D gene for the incorporation of multiple PTCs resulted in a progeny virus harboring three PTCs with high replicative capacity and genetic stability. In mouse and pig models, compared with inactivated vaccines, the SVV-PTC vaccination elicited high antibody titers at 14 days post-primary immunization and induced a stronger Th1-biased cellular immune response. We further validated the safety and protective efficacy of the SVV-PTC vaccine candidate in swine models, confirming its complete attenuation in vivo, absence of horizontal transmission, and protective efficacy comparable to that of the commercial inactivated SVV vaccine. In conclusion, the development of live but replication-incompetent attenuated vaccines using sup-tRNA is a promising prevention and control strategy, providing a new insight for the development of novel SVV vaccines.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-026-01507-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Seneca Valley virus (SVV) causes porcine idiopathic vesicular disease, severely endangering the economic benefits of the swine industry. Artificial control of viral replication via the introduction of premature termination codons (PTCs) into the viral genome using suppressor tRNAs (sup-tRNAs) is a promising strategy for developing efficient vaccines. In this study, optimization of the SVV 3D gene for the incorporation of multiple PTCs resulted in a progeny virus harboring three PTCs with high replicative capacity and genetic stability. In mouse and pig models, compared with inactivated vaccines, the SVV-PTC vaccination elicited high antibody titers at 14 days post-primary immunization and induced a stronger Th1-biased cellular immune response. We further validated the safety and protective efficacy of the SVV-PTC vaccine candidate in swine models, confirming its complete attenuation in vivo, absence of horizontal transmission, and protective efficacy comparable to that of the commercial inactivated SVV vaccine. In conclusion, the development of live but replication-incompetent attenuated vaccines using sup-tRNA is a promising prevention and control strategy, providing a new insight for the development of novel SVV vaccines.

抑制因子trna介导的条件复制活疫苗可有效保护猪免受塞内卡谷病毒的攻击。
塞内卡谷病毒(SVV)引起猪特发性水疱病,严重危害养猪业的经济效益。利用抑制trna (sup- trna)在病毒基因组中引入过早终止密码子(ptc)来人工控制病毒复制是开发高效疫苗的一种很有前景的策略。本研究通过对SVV 3D基因的优化,获得了包含三个ptc的子代病毒,具有较高的复制能力和遗传稳定性。在小鼠和猪模型中,与灭活疫苗相比,SVV-PTC疫苗在初次免疫后14天引起高抗体滴度,并诱导更强的th1偏向细胞免疫反应。我们进一步在猪模型中验证了SVV- ptc候选疫苗的安全性和保护功效,证实其在体内完全衰减,没有水平传播,并且保护功效与商业灭活SVV疫苗相当。综上所述,利用sup-tRNA开发无复制能力的减毒活疫苗是一种很有前景的防控策略,为开发新型SVV疫苗提供了新的思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书